证券代码：300341 证券简称：麦克奥迪 公告编号：2023-020 麦克奥迪（厦门）电气股份有限公司 关于参加厦门辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与广大投资者的沟通和交流，麦克奥迪（厦门）电气股份有限 公司（以下简称"公司"）将参加由厦门证监局、厦门上市公司协会与深圳市全景 网络有限公司联合举办的"2023 年厦门辖区上市公司投资者网上集体接待日活 动"（以下简称"本次活动"），现将相关事项公告如下： 一、召开时间 2023 年 5 月 12 日（星期五）14:30－16:15 二、召开方式 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参与 本次互动交流。 三、出席活动的人员 公司出席本次活动的人员有：公司董事长杨文良先生、副总经理兼董事会秘 书李臻先生、财务副总监刘亚军先生、监事陈培堃先生。 四、投资者问题征集及方式 为进一步做好中小投资者保护工作，充分尊重 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥348,643,873.82, a decrease of 3.02% compared to ¥359,515,780.05 in the same period last year[4] - Net profit attributable to shareholders was ¥38,942,232.67, down 14.62% from ¥45,610,282.01 year-on-year[4] - Basic and diluted earnings per share decreased by 15.10% to ¥0.0759 from ¥0.0894 in the same period last year[4] - Total operating revenue for Q1 2023 was CNY 348,643,873.82, a decrease of 3.4% compared to CNY 359,515,780.05 in Q1 2022[17] - Net profit for Q1 2023 was CNY 40,564,635.86, down 14.6% from CNY 47,191,169.22 in Q1 2022[19] - Earnings per share for Q1 2023 were CNY 0.0759, compared to CNY 0.0894 in the same period last year, reflecting a decline of 15.6%[20] - The company recorded a comprehensive income of CNY 32,129,339.87 for Q1 2023, down from CNY 44,069,776.67 in the same period last year[20] Cash Flow - The net cash flow from operating activities increased significantly by 316.07% to ¥59,298,306.46, compared to ¥14,251,925.13 in the previous year[4] - The company reported a net increase in cash flow from operating activities due to increased collections from receivables in the medical segment[9] - The net cash flow from operating activities for Q1 2023 was ¥59,298,306.46, a significant increase from ¥14,251,925.13 in Q1 2022, representing a growth of approximately 317%[23] - Cash inflow from operating activities increased to CNY 420,542,720.06 in Q1 2023, up from CNY 340,370,457.92 in Q1 2022, representing a growth of 23.6%[22] - The company reported a total cash outflow from operating activities of ¥361,244,413.60, which is higher than ¥326,118,532.79 in the previous year, indicating increased operational expenses[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,231,418,082.18, a slight increase of 0.03% from ¥2,230,637,587.80 at the end of the previous year[4] - The company's equity attributable to shareholders increased by 2.36% to ¥1,591,989,303.98 from ¥1,555,240,324.80 at the end of the previous year[4] - Total liabilities as of Q1 2023 were CNY 506,217,833.55, down from CNY 538,857,604.09 in the previous year[19] - Current liabilities decreased to ¥473,065,289.90 from ¥505,000,513.29, a reduction of approximately 6.31%[15] - Non-current assets total ¥583,542,857.19, up from ¥574,666,106.22, indicating an increase of about 1.52%[15] Investments - The company’s investment activities generated a net cash outflow of ¥40,998,500, a decrease of 4,416,230 compared to the previous year, mainly due to investments in the renovation of the second phase of the factory[9] - Total cash outflow from investing activities was ¥41,001,003.82, compared to ¥17,288,954.07 in the previous year, indicating a year-over-year increase of about 137.5%[23] - The net cash flow from investing activities was -¥40,998,482.71, a decline from a positive cash flow of ¥3,163,795.93 in Q1 2022[23] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 21,520[11] - The largest shareholder, Beijing Yizhuang Investment Holding Co., Ltd., holds 29.80% of shares, totaling 152,997,984 shares[11] Other Financial Metrics - The company experienced a decrease in financial expenses by ¥6,222,400, primarily due to the impact of the continuous depreciation of the RMB[8] - The company has a long-term investment of ¥3,428,447.14, down from ¥3,667,581.63, a decrease of approximately 6.53%[15] - Research and development expenses for Q1 2023 were CNY 14,379,974.40, a decrease of 6.4% from CNY 15,361,562.74 in Q1 2022[17] - The company reported a financial expense of CNY -3,515,470.42 in Q1 2023, a significant improvement compared to CNY 2,706,932.75 in Q1 2022[19] - The cash inflow from other financing activities was ¥855,000.00, a decrease from ¥1,400,000.00 in Q1 2022, indicating a reduction in external financing sources[23] Strategic Initiatives - The company is actively exploring new product development and market expansion strategies, although specific details were not disclosed in the report[12] Audit Information - The company did not conduct an audit for the Q1 2023 report, as stated in the audit report[24]

Financial Performance - The company's operating revenue for 2022 was CNY 1,793,966,267, representing a 22.48% increase compared to CNY 1,464,754,511 in 2021[26]. - Net profit attributable to shareholders for 2022 was CNY 261,140,467, a 46.68% increase from CNY 178,037,346 in 2021[26]. - The basic earnings per share for 2022 was CNY 0.5100, up 46.13% from CNY 0.3490 in 2021[26]. - The total assets at the end of 2022 reached CNY 2,230,637,578, marking a 19.77% increase from CNY 1,861,536,920 at the end of 2021[26]. - The net cash flow from operating activities for 2022 was CNY 239,499,904, a slight increase of 2.19% from CNY 234,367,769 in 2021[26]. - The company achieved a total revenue of 1,793.97 million yuan in 2022, representing a year-on-year growth of 22.48%[47]. - The net profit attributable to shareholders was 261.14 million yuan, an increase of 46.68% compared to the previous year[47]. - Basic earnings per share rose to 0.5100 yuan, reflecting a growth of 46.13% year-on-year[47]. Dividend Policy - The company plans to distribute a cash dividend of 1.1 RMB per 10 shares to all shareholders, based on a total of 513,393,236 shares[6]. - The company plans to distribute a cash dividend of ¥1.1 per 10 shares, totaling ¥56,473,255.96, which represents 100% of the profit distribution amount[164]. - The company’s cash dividend policy stipulates that at least 20% of the distributable profit should be allocated as cash dividends if there are significant capital expenditure arrangements[161]. - The company’s profit distribution plan must be approved by the board and the shareholders' meeting, ensuring independent directors and minority shareholders have a voice[163]. Operational Risks and Management - The company emphasizes the importance of risk awareness regarding future operational plans and performance forecasts, indicating that these do not constitute commitments to investors[3]. - The company has disclosed potential operational risks and corresponding countermeasures in the management discussion and analysis section[4]. - The company is focusing on enhancing operational efficiency and reducing costs through strategic planning and internal restructuring in response to global uncertainties[48]. - The company recognizes the risk of technology updates and product development, emphasizing the need for continuous innovation and market responsiveness[108]. Business Segments and Growth Areas - The company operates in three core business areas: medical business, optoelectronic business, and smart electrical business, focusing on integrated innovation to drive industrial upgrades[42]. - The medical business includes digital pathology scanning and application systems, remote expert diagnostic services, and AI-assisted diagnostic products, covering over 2,500 medical institutions nationwide[43]. - The optoelectronic business is experiencing rapid growth, with domestic manufacturers increasingly replacing imports in the microscope industry, driven by advancements in precision manufacturing[39]. - The smart electrical business is benefiting from the increasing market size of the high-voltage switch industry, providing a broad market space for epoxy insulation products[41]. Research and Development - The company is focusing on R&D projects aimed at enhancing product intelligence and performance, including the development of high-strength epoxy resin formulations and new production processes for high-voltage insulation components[77]. - The company is investing in research and development to introduce innovative solutions that align with market demands and consumer preferences[128]. - The company has obtained 13 invention patents, 11 utility model patents, and 17 software copyrights in the medical business sector, showcasing its commitment to innovation[57]. - The company is developing a high-throughput digital slice scanner to meet the increasing demands of large hospitals and third-party diagnostic institutions[78]. Market Expansion and Strategy - The company plans to expand its applications in precision instruments for industrial inspection and scientific research in 2023, focusing on sectors such as new energy, electronics, and biomedicine[44]. - The company plans to expand its market presence through strategic partnerships and potential acquisitions to enhance growth opportunities[128]. - Market expansion plans include entering two new international markets by Q3 2023, targeting a 5% increase in overall market share[133]. Corporate Governance - The company has established a complete and independent business system, ensuring autonomy in operations and decision-making[120]. - The board of directors consists of 12 members, including 4 independent directors, complying with legal and regulatory requirements[114]. - The company has a robust internal control system that meets national legal requirements and effectively mitigates operational risks[118]. - The company has established a transparent information disclosure system, ensuring timely and accurate communication with investors[118]. Environmental and Social Responsibility - The company is committed to environmental protection and aims to establish a low-carbon electrical industrial park in Xiamen[185]. - The company actively participates in social responsibility initiatives, including virus prevention and employee health protection during the reporting period[186]. - The company emphasizes the protection of investor rights, particularly for small and medium investors, by enhancing corporate governance and compliance with regulations[185]. Financial Management and Audit - The company has maintained a complete and independent financial management system, with separate bank accounts and independent tax obligations[121]. - The domestic accounting firm, Rongcheng CPA, has been engaged for 4 consecutive years, with an audit fee of 1.8 million yuan[198]. - The company has not changed its accounting firm, indicating stability in its financial reporting practices[198]. Employee and Talent Management - The total number of employees at the end of the reporting period was 2,136, with 1,090 in production, 224 in sales, and 320 in technical roles[153]. - The company has established a three-year shareholder return plan (2021-2023) to ensure a stable and scientific dividend distribution mechanism[158]. - The company plans to further enhance its talent training system in 2023, leveraging internal resources to foster a learning-oriented environment[156].

麦克奥迪(厦门)电气股份有限公司（以下简称"公司"）已于 2023 年 04 月 11 日在巨潮资讯网上披露了《2022 年度报告全文》及《2022 年度报告摘要》。 为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定 于 2023 年 04 月 28 日（星期五）15:00-17:00 在"价值在线"（www.ir-online.cn） 举办麦克奥迪(厦门)电气股份有限公司 2022 年度业绩说明会，与投资者进行沟 会议召开时间：2023 年 04 月 28 日（星期五）15:00-17:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） 会议问题征集： 投 资 者 可 于 2023 年 04 月 28 日 前 访 问 网 址 https://eseb.cn/13Ie5sFtYDS 或使用微信扫描下方小程序码进行会前提 问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍 关注的问题进行回答。 通和交流，广泛听取投资者的意见和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2023 年 04 月 28 日（星期五）15:00-1 ...

编号：2021-001 证券代码：300341 证券简称： 麦克奥迪 | --- | --- | --- | |------------------------|-----------------------------------------------------|----------------------------------------------------------| | | | | | 投资者关系活动类别 | ■特定对象调研 | □分析师会议 | | | □媒体调研 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他（ | ） | | 参与单位名称及人员姓名 | 银华基金：陈日华、长信基金：陈言午 中泰证券：张哲源 | | | 时间 | 2021 年12月 07日15:30 | | | 地点 | 公司培训室 | | | 上市公司接待人员姓名 | 杨文良、胡春华、李臻 | | | 投资者关系活动主要内容 | 一、参观公司的方案解决中心及生产车间； | | | 介绍 | 二、对公司的整体情况进行介绍。 | | | | 三、互动交流摘要： ...

麦克奥迪（厦门）电气股份有限公司 2022 年第三季度报告 证券代码：300341 证券简称：麦克奥迪 公告编号：2022-051 麦克奥迪（厦门）电气股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 456,067,517.72 | 18.84% | 1,261,535,604.44 | 24.61% | | ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥805,468,086.72, representing a 28.13% increase compared to ¥628,638,560.32 in the same period last year[23]. - The net profit attributable to shareholders was ¥108,807,447.40, which is a 51.68% increase from ¥71,733,560.08 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was ¥106,544,601.29, up 61.55% from ¥65,952,847.11 year-on-year[23]. - The basic earnings per share increased by 50.71% to ¥0.2119 from ¥0.1406 in the same period last year[23]. - The total revenue for the first half of 2022 was 733,153,000,000 CNY, reflecting a year-on-year growth of 8.5%[181]. - The net profit for the first half of 2022 was 14,707,500,000 CNY, which is a 2.6% increase compared to the same period last year[181]. - The total comprehensive income for the first half of 2022 was 31.48 million, showing a significant increase compared to the previous year[185]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,960,636,781.81, a 5.32% increase from ¥1,861,536,925.53 at the end of the previous year[23]. - The total liabilities decreased to CNY 469,090,185.54 from CNY 483,440,978.67, a reduction of about 2.9%[158]. - The equity attributable to the parent company increased to CNY 1,361,074,135.35 from CNY 1,251,194,710.14, reflecting a growth of approximately 8.8%[158]. - Cash and cash equivalents decreased to CNY 413,783,337, accounting for 21.10% of total assets, down from 28.51% at the end of the previous year[63]. - Accounts receivable increased to CNY 553,419,089, representing 28.23% of total assets, with a year-over-year growth attributed to increased sales across three major business segments[63]. Business Segments and Strategy - The company focuses on three core businesses: medical, optoelectronics, and smart electrical, aiming to integrate traditional operations into advanced manufacturing[31]. - The medical business includes digital pathology systems and AI-assisted diagnostic services, enhancing capabilities through big data and AI technologies[32]. - The company plans to expand its market presence in life sciences, smart healthcare, and industrial testing sectors, leveraging its existing advantages in education[31]. - The company is gradually developing its e-commerce operations as a significant future business expansion channel[40]. - The company aims to integrate IoT technology into its epoxy insulation products, enhancing their intelligence and contributing to smart city development[40]. Research and Development - The company emphasizes technological innovation and has established research stations to maintain its competitive edge in the industry[34]. - The company accumulated over 12 invention patents, 10 utility model patents, and 17 software copyrights in the medical business segment by the end of the reporting period[50]. - The optical business segment has obtained a total of 82 invention patents and 95 software copyrights, showcasing its strong R&D capabilities[51]. - The company is focusing on R&D innovations in material technology to enhance its core insulation components for new energy applications[47]. Market and Competition - The company is a leading player in the domestic optical microscope industry, providing better cost-performance compared to international brands and higher overall performance than domestic competitors[46]. - The third-party diagnostic business has partnered with the National Health Commission to create a "digital pathology remote diagnosis and quality control platform," covering over 1,800 hospitals and completing 200,000 remote diagnoses in the past three years[45]. - The company is actively participating in international competition and expanding its market share in the global arena[46]. Risk Management - The management has disclosed potential risks and countermeasures in the report, emphasizing the importance of risk awareness for investors[3]. - The company faces risks from macroeconomic changes, including inflation and raw material price volatility, which may impact profit margins[82]. - The company has implemented measures to lock in exchange rates and mitigate foreign exchange risks through forward contracts[86]. Corporate Governance and Shareholder Engagement - The company emphasizes protecting the rights of investors, particularly small and medium-sized investors, by enhancing corporate governance and communication[105]. - The company held two temporary shareholder meetings with participation rates of 64.99% and 64.96% respectively, reflecting strong investor engagement[90]. - The company has introduced a stock incentive plan to motivate employees and align their interests with company performance[94]. Sustainability and Social Responsibility - The company initiated a zero-carbon construction project in its Xiamen industrial park, aiming for carbon neutrality through distributed solar power and energy storage[103]. - The company actively participates in social responsibility initiatives, including pandemic prevention and employee health protection[106]. - The company is committed to sustainable development and aims to establish a low-carbon electrical industrial park in Xiamen[105].

证券代码：300341 证券简称：麦克奥迪 公告编号：2022-031 麦克奥迪（厦门）电气股份有限公司 关于参加厦门辖区上市公司2021年年报业绩说明会暨 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 麦克奥迪（厦门）电气股份有限公司（以下简称"公司"） 已于 2022 年 04 月 07 日在巨潮资讯网（http://www.cninfo.com.cn/）披露了公司 2021 年年度报 告及其摘要，为便于广大投资者进一步了解公司 2021 年度经营情况，加强与广 大投资者的沟通和交流，公司将参加由厦门证监局、厦门上市公司协会与深圳市 全景网络有限公司联合举办的"2021 年年报业绩说明会暨投资者网上集体接待 日"活动。具体情况如下： 一、召开时间 2022 年 5 月 10 日（星期二）14:30－16:00 二、召开方式 本次活动将在深圳市全景网络有限公司提供的网上平台采取网络远程的方 式举行，投资者可登录"全景投资者关系互动平台"（http://ir.p5w.net）参与本 次互动交流。 三、出席活动的人员 公司出席本 ...

Financial Performance - The company's revenue for Q1 2022 was ¥359,515,780.05, representing a 24.09% increase compared to ¥289,716,975.56 in the same period last year[3] - Net profit attributable to shareholders was ¥45,610,282.01, up 29.71% from ¥35,164,208.37 year-on-year[3] - Basic and diluted earnings per share increased by 29.75% to ¥0.0894 from ¥0.0689 in the same period last year[3] - The total operating revenue for Q1 2022 was CNY 359,515,780.05, representing an increase of 24.1% compared to CNY 289,716,975.56 in the same period last year[15] - The net profit for Q1 2022 reached CNY 47,191,169.22, a 26.9% increase from CNY 37,206,452.32 in Q1 2021[16] - The operating profit for Q1 2022 was CNY 58,774,362.85, compared to CNY 46,618,308.49 in the previous year, marking a growth of 25.9%[15] Cash Flow - The net cash flow from operating activities decreased by 72.51% to ¥14,251,925.13, down from ¥51,846,277.69 in the previous year[3] - The cash flow from operating activities for Q1 2022 was CNY 14,251,925.13, a decrease of 72.5% from CNY 51,846,277.69 in Q1 2021[18] - The net cash flow from investment activities was 3,163,795.93 CNY, compared to a negative cash flow of -20,634,780.38 CNY in the previous year[20] - The cash flow from financing activities resulted in a net outflow of -41,107,542.52 CNY, compared to -11,846,275.79 CNY in the previous year[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,894,750,084.78, a 1.78% increase from ¥1,861,536,925.53 at the end of the previous year[3] - Total liabilities amounted to CNY 1,361,970,870.49, with current liabilities including accounts payable at CNY 151,641,669.50[12] - The total liabilities as of Q1 2022 were CNY 466,767,628.59, a slight decrease from CNY 483,440,978.67 in the previous year[14] - The company’s equity position remains strong with total equity reflecting the growth in assets and liabilities management[12] Shareholder Information - The company reported a decrease in financial expenses to CNY 2,706,932.75 from CNY 5,537,831.65 in the previous year, indicating improved cost management[15] - The top shareholder, Beijing Yizhuang Investment Holding Co., Ltd., holds 29.99% of shares, indicating significant ownership concentration[8] Operational Efficiency - The balance of accounts receivable decreased by 44.42% to ¥8,536,600 from the beginning of the period, primarily due to the use of commercial acceptance bills for payments[6] - Prepayments increased by 102.35% to ¥21,145,500, mainly due to an increase in prepayments in the medical sector[6] - The company is actively managing its receivables and inventory to optimize cash flow and operational efficiency[12] - The company experienced a significant increase in research and development expenses, totaling CNY 15,361,562.74, compared to CNY 14,839,885.57 in Q1 2021, reflecting a focus on innovation[15] Cash Reserves - Cash and cash equivalents decreased to CNY 481,328,478.98 from CNY 530,642,545.42, indicating a reduction in cash reserves[11] - The ending balance of cash and cash equivalents was 479,640,726.50 CNY, down from 486,028,671.73 CNY year-over-year[20]

Financial Performance - The company reported a significant increase in revenue, with a total of 510,163,336 shares as the basis for a cash dividend of 0.70 RMB per 10 shares[11]. - The company's operating revenue for 2021 was ¥1,464,754,512.53, representing a 23.44% increase compared to ¥1,186,600,559.29 in 2020[24]. - The net profit attributable to shareholders for 2021 was ¥178,037,346.34, an increase of 28.03% from ¥139,055,974.01 in 2020[24]. - The net profit after deducting non-recurring gains and losses was ¥152,475,339.27, up 39.85% from ¥109,027,081.61 in 2020[24]. - The net cash flow from operating activities reached ¥234,367,769.64, a 37.59% increase from ¥170,335,327.65 in 2020[24]. - The total assets at the end of 2021 were ¥1,861,536,925.53, reflecting a 9.16% increase from ¥1,705,335,204.93 at the end of 2020[24]. - The net assets attributable to shareholders increased by 15.56% to ¥1,251,194,710.14 at the end of 2021 from ¥1,082,726,957.70 at the end of 2020[24]. - The company achieved a total revenue of 1,464.75 million CNY in the reporting period, representing a year-on-year growth of 23.44%[43]. - The net profit attributable to shareholders reached 17,803.73 million CNY, an increase of 28.03% compared to the previous year[43]. - The basic earnings per share were 0.3490 CNY, reflecting a growth of 28.03% year-on-year[43]. Market Presence and Strategy - Approximately 45% of the company's total revenue comes from overseas markets, indicating a strong international presence[9]. - The company aims to enhance its market presence through strategic partnerships and regional laboratory expansions[34]. - The company is focusing on expanding its market presence and enhancing its product offerings through strategic appointments and board restructuring[132]. - The company plans to enhance market development capabilities, leveraging domestic manufacturing to deepen the domestic market and using its Hong Kong subsidiary to expand overseas[107]. - The company is actively seeking opportunities for mergers and acquisitions to bolster its market position and expand its product portfolio[132]. Innovation and R&D - The company is adapting to macroeconomic uncertainties by focusing on innovation in its two business systems: electrical energy technology and smart optical applications[5]. - The company is focused on integrating innovation in smart grids, ultra-high voltage, and artificial intelligence to adapt to environmental changes[5]. - The company is focusing on the development of digital pathology and AI-assisted diagnostic systems, which are expected to be key competitive areas in the future[34]. - The company is committed to developing smart electrical components and integrating IoT technologies to advance towards environmentally friendly and intelligent solutions[42]. - The company is developing a new generation of cervical cytology auxiliary diagnostic systems to improve diagnostic accuracy and reduce missed diagnoses[83]. - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing product efficiency and sustainability[144]. Operational Risks and Challenges - The company faces risks from raw material price fluctuations, particularly in electronic components and commodities like oil and copper, which could lead to a decline in gross margin[8]. - The operational management risk has increased due to the diverse industry operations and the need for enhanced asset control and resource allocation[7]. - The company acknowledges the impact of currency exchange rate fluctuations on its revenue and profit due to foreign currency sales[9]. - The company faces risks from macroeconomic changes, including geopolitical tensions and the ongoing pandemic, which may impact its business operations[111]. - The company has implemented unified procurement strategies to enhance scale efficiency and mitigate price risks[114]. Governance and Compliance - The board of directors consists of 12 members, including 4 independent directors, ensuring compliance with legal and regulatory requirements[119]. - The company maintains complete independence in its operations, with no shared assets or financial resources with its controlling shareholder[121]. - The company has a performance evaluation and incentive mechanism in place for its directors and senior management, aligning with its development status[122]. - The company has established a comprehensive internal control system that meets national legal requirements and effectively protects investors' rights[122]. - The company has committed to improving corporate governance and compliance to protect the interests of investors, especially minority shareholders[191]. Employee and Talent Development - The company has a stable management and technical team, which contributes to its competitive advantage in the market[44]. - The company emphasizes talent development and employee satisfaction as part of its human resources strategy[191]. - The total number of employees at the end of the reporting period was 2,193, with various roles across production, sales, technical, finance, administration, and others[161]. - The company has implemented a fair and transparent compensation policy, ensuring internal equity and external competitiveness in employee salaries[163]. - The company plans to enhance its training programs, focusing on key talent development and increasing the total training hours compared to 2020[164]. Future Outlook - The company has set a revenue guidance of 1.8 billion RMB for the next fiscal year, projecting a growth rate of 20%[144]. - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[148]. - The company plans to pursue strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential targets[150]. - The company is likely to pursue new strategies for growth, including potential mergers and acquisitions, given the changes in its leadership and board composition[134].